New immunotherapy combo tested for incurable cancers

NCT ID NCT02537418

Ongoing Disease control Sponsor: Canadian Cancer Trials Group Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two immunotherapy drugs, durvalumab and tremelimumab, alone or together with standard chemotherapy in people with advanced solid tumors that cannot be cured. The main goal is to find the highest safe dose that does not cause severe side effects. About 153 participants will take part, and the study also looks at how well the treatment shrinks tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID MALIGNANCIES

Contacts and locations

Locations

BCCA - Vancouver Cancer Centre

Vancouver, British Columbia, V5Z 4E6, Canada
CHUM - Hopital Notre-Dame

Montreal, Quebec, H2L 4M1, Canada
Cancer Centre of Southeastern Ontario at Kingston

Kingston, Ontario, K7L 5P9, Canada
Juravinski Cancer Centre at Hamilton Health Sciences

Hamilton, Ontario, L8V 5C2, Canada
Ottawa Hospital Research Institute

Ottawa, Ontario, K1H 8L6, Canada
Tom Baker Cancer Centre

Calgary, Alberta, T2N 4N2, Canada
University Health Network

Toronto, Ontario, M5G 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.